Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
MBOT 
Microbot Medical Inc (MBOT)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/01/2025: MBOT (4-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Above Average Performance
These Stocks/ETFs, based on Upturn Advisory, frequently surpass the market, reflecting reliable and trustworthy advice.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $9
1 Year Target Price $9
| 0 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -4.37% | Avg. Invested days 37 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 07/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 95.40M USD | Price to earnings Ratio - | 1Y Target Price 9 |
Price to earnings Ratio - | 1Y Target Price 9 | ||
Volume (30-day avg) 1 | Beta 1.15 | 52 Weeks Range 0.82 - 3.38 | Updated Date 07/1/2025 |
52 Weeks Range 0.82 - 3.38 | Updated Date 07/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.64 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -40.06% | Return on Equity (TTM) -66.48% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 64961664 | Price to Sales(TTM) - |
Enterprise Value 64961664 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -0.89 | Shares Outstanding 37858300 | Shares Floating 36377812 |
Shares Outstanding 37858300 | Shares Floating 36377812 | ||
Percent Insiders 0.66 | Percent Institutions 6.41 |
Analyst Ratings
Rating 1 | Target Price 9 | Buy 1 | Strong Buy - |
Buy 1 | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Microbot Medical Inc
Company Overview
History and Background
Microbot Medical Inc. was founded in 2010. It focuses on developing and commercializing micro-robotic endoluminal technologies for various medical applications. Key milestones include the development of the LIBERTY Robotic System and ongoing clinical trials.
Core Business Areas
- Robotic Endoluminal Surgery: Development and commercialization of micro-robotic systems for minimally invasive surgical procedures within the human body's natural lumens.
Leadership and Structure
Harel Gadot serves as the CEO and Chairman. The company operates with a management team overseeing research and development, clinical trials, and commercialization efforts. A board of directors provides strategic oversight.
Top Products and Market Share
Key Offerings
- LIBERTY Robotic System: A single-use robotic micro-catheter designed to navigate tortuous vasculature. While there is no direct market share data, the target market includes peripheral vascular interventions. Competitors include established players in the interventional cardiology and radiology spaces like Abbott (ABT), Medtronic (MDT) and Boston Scientific (BSX).
Market Dynamics
Industry Overview
The medical robotics industry is experiencing rapid growth, driven by the demand for minimally invasive procedures and improved patient outcomes. Technological advancements and an aging population are key growth drivers.
Positioning
Microbot Medical is positioned as an innovator in the micro-robotic surgery space, focusing on developing unique solutions for navigating complex anatomies. Their competitive advantage lies in their proprietary technology and single use design.
Total Addressable Market (TAM)
The overall medical robotics market is projected to reach hundreds of billions of dollars in the coming years. Microbot Medical is targeting specific segments within this market, such as peripheral vascular interventions, which represent a multi-billion dollar opportunity. Microbot is positioned to capture a portion of this TAM through its innovative robotic platform.
Upturn SWOT Analysis
Strengths
- Proprietary micro-robotic technology
- Potential for minimally invasive procedures
- Strong intellectual property portfolio
- Experienced management team
Weaknesses
- Limited commercialized products
- High reliance on regulatory approvals
- Significant dependence on future funding
- Small market capitalization
Opportunities
- Expansion into new therapeutic areas
- Partnerships with larger medical device companies
- Increasing adoption of robotic surgery
- Favorable regulatory environment
Threats
- Competition from established medical device companies
- Technological obsolescence
- Unfavorable clinical trial results
- Economic downturn impacting healthcare spending
Competitors and Market Share
Key Competitors
- ABT
- MDT
- BSX
Competitive Landscape
Microbot Medical faces stiff competition from established medical device companies with significant resources and established market presence. However, Microbot Medical's innovative micro-robotic technology could allow it to capture a niche market in minimally invasive procedures.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is limited due to its development stage, but growth will be primarily determined through approval of LIBERTY and other products.
Future Projections: Future growth depends on successful clinical trials, regulatory approvals, and commercialization efforts. Analyst estimates vary widely due to the inherent uncertainties of the medical device industry.
Recent Initiatives: Recent initiatives include advancing clinical trials for the LIBERTY Robotic System and pursuing regulatory approvals. There is also a continued push to expand IP protections.
Summary
Microbot Medical is a high-risk, high-reward development-stage company focused on micro-robotic surgery. Its innovative technology has the potential to disrupt the medical device industry, but it faces significant challenges related to regulatory approvals, competition, and funding. Successful clinical trials and commercialization are critical for future success. The company needs to secure partnerships to bolster its market presence.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports (where available)
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Investment decisions should be based on thorough research and consultation with a financial professional. Market share estimates are based on available industry reports and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Microbot Medical Inc
Exchange NASDAQ | Headquaters Hingham, MA, United States | ||
IPO Launch date 1992-03-25 | Co-Founder, President, CEO & Chairman Mr. Harel Gadot | ||
Sector Healthcare | Industry Medical Instruments & Supplies | Full time employees 20 | Website https://microbotmedical.com |
Full time employees 20 | Website https://microbotmedical.com | ||
Microbot Medical Inc., a clinical-stage medical device company, engages in the research, design, and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space in Israel and the United States. The company offers LIBERTY, an endovascular robotic surgical system which allows physicians to conduct a catheter-based procedure from outside the catheterization laboratory, and avoid radiation exposure, physical strain, and the risk of cross contamination for use in cardiovascular, peripheral, endovascular, and neurovascular operations. It also provides NovaCross, an intellectual property and technology in the field of intraluminal revascularization devices with anchoring mechanism and integrated microcatheter. The company has a collaboration agreement with Corewell Health for the development of LIBERTY endovascular robotic system; and Emory University, in connection with autonomous robotics in endovascular procedures. Microbot Medical Inc. was founded in 2010 and is based in Hingham, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.